What Analysts Recommend for GlaxoSmithKline and Novo Nordisk

Which is a better pick?

GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis. The consensus recommendation for GlaxoSmithKline is a “buy.” Wall Street analysts expect an upside potential of 10.47% for GlaxoSmithKline based on the company’s closing price on June 26 and a target price of $44.33. Out of four analysts covering GlaxoSmithKline, two recommend a “strong buy,” and two recommend a “hold.”

Wall Street analysts expect an upside potential of 5.87% for Novo Nordisk based on the company’s closing price on June 26 and a target price of $53.90. Only one analyst covers the company and has recommended a “hold.”

Stock price movements and valuation

On June 26, GlaxoSmithKline closed at $40.13, 1.23% lower than the previous close, 10.22% higher than its 52-week low price of $36.41, and 5.17% lower than its 52-week high price of $42.32. The company’s market capitalization is $100.96 billion, and its PE, forward PE, PE to growth (or PEG), price-to-sales (or PS), price-to-book (or PB), and price-to-cash ratios were 19.52x, 13.45x, 2.19x, 2.54x, 19.39x, and 18.87x, respectively.

On June 26, Novo Nordisk closed at $50.91, 0.53% lower than the previous close, 23.48% higher than its 52-week low price of $41.23, and 3.63% lower than its 52-week high price of $52.83. The company’s market capitalization is $95.51 billion and PE, forward PE, PEG, PS, and PB ratios were 21.19x, 18.09x, 2.30x, 5.53x, and 17.03x, respectively.

Compared to Novo Nordisk, GlaxoSmithKline is trading at lower PE, forward PE, PEG, and PS ratios, but higher PB ratio.